Coronavirus disease 2019 in solid organ transplant recipients in the setting of proactive screening and contact tracing of Qatar

Rand A. Alattar1,*, Shahd H. Shaar1,*, Muftah Othman2, Sulieman H. Abu Jarir1,3, Samar M. Hashim1,3, Fatima Iqbal1, Fatima Rustom1, Muna A. Almaslamani1,3, Ali S. Omrani1,3*

ABSTRACT

Background: Clinical data on Coronavirus Disease 2019 (COVID-19) in solid organ transplant (SOT) recipients are limited. We herein report the initial clinical experience with COVID-19 in SOT recipients in Qatar.

Methods: All SOT recipients with laboratory-confirmed COVID-19 up to May 23, 2020 were included. Demographic and clinical data were extracted retrospectively from the hospital’s electronic health records. Categorical data are presented as frequency and percentages, while continuous variables are summarized as medians and ranges.

Results: Twenty-four SOT recipients were identified (kidney 16, liver 6, heart 1, and liver and kidney 1). Organ transplantation preceded COVID-19 by a median of 60 months (range 1.7–184). The median age was 57 years (range 24–72), and 9 (37.5%) transplant recipients were females. Five (21%) asymptomatic patients were diagnosed through proactive screening. For the rest, fever (15/19) and cough (13/19) were the most frequent presenting symptoms. Five (20.8%) patients required invasive mechanical ventilation in the intensive care unit (ICU). Eleven (46%) patients developed acute kidney injury, including three in association with drug-drug interactions involving investigational COVID-19 therapies. Maintenance immunosuppressive therapy was modified in 18 (75%) patients, but systemic corticosteroids were not discontinued in any. After a median follow-up of 226 days (26–272), 20 (83.3%) patients had been discharged home, 2 (8.3%) were still hospitalized, 1 (4.2%) was still in the ICU, and 1 (4.2%) had died.

Address for Correspondence:
Ali S. Omrani1,3*
1Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar
2Division of Nephrology, Hamad Medical Corporation, Doha, Qatar
3Division of Infectious Diseases, Hamad Medical Corporation, Doha, Qatar
Email: aomrani@hamad.qa

http://dx.doi.org/10.5339/qmj_2021.23
Submitted: 15 January 2021
Accepted: 07 March 2021
© 2021 Alattar, Shaar, Othman, Abu Jarir, Hashim, Iqbal, Rustom, Almaslamani, Omrani, licensee HBKU Press. This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

Cite this article as: Alattar RA, Shaar SH, Othman M, Abu Jarir SH, Hashim SM, Iqbal F, Rustom F, Almaslamani MA, Omrani AS. Coronavirus disease 2019 in solid organ transplant recipients in the setting of proactive screening and contact tracing of Qatar, Qatar Medical Journal 2021:23 http://dx.doi.org/10.5339/qmj_2021.23
Conclusions: Our results suggest that asymptomatic COVID-19 is possible in SOT recipients and that overall outcomes are not uniformly worse than those in the general population. The results require confirmation in large, international cohorts.

Keywords: coronavirus, SARS-CoV-2, transplantation, middle east, Qatar

INTRODUCTION

By January 2021, the global number of infections caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the cause of Coronavirus Disease 2019 (COVID-19), was approaching 90 million, with nearly 2 million associated deaths. Clinical outcomes associated with COVID-19 appear to be considerably worse in older individuals and in those with chronic medical conditions such as hypertension, diabetes mellitus, and chronic kidney disease. In general, respiratory viral infections in solid organ transplant (SOT) recipients are associated with more rapidly progressive and severe disease, prolonged viral shedding, and a higher risk of mortality. However, SOT recipients are under-represented in large COVID-19 cohorts, and the interaction between COVID-19 and SOT has not been fully elucidated.

While the immune-suppressed status of SOT recipients may increase their risk of severe COVID-19 and mortality, it is possible that chronic immune suppression may mitigate some of the severe inflammation-driven COVID-19 manifestations. We herein report the clinical characteristics, management, and outcomes of SOT-associated COVID-19 in Qatar.

MATERIALS AND METHODS

Hamad Medical Corporation encompasses multiple hospital facilities and provides all COVID-19 medical care for the population of Qatar. SARS-CoV-2 infection was diagnosed on respiratory tract specimens by real-time polymerase chain reaction (RT-PCR) assays using the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, Waltham, Massachusetts) or the Cobas SARS-CoV-2 Test (Roche Diagnostics, Rotkreuz, Switzerland). SARS-CoV-2 testing was offered to all individuals presenting with symptoms suggestive of COVID-19, known close contacts of confirmed cases including healthcare workers, and all returning travelers.

The Communicable Diseases Center's COVID-19 database includes records of all RT-PCR–confirmed SARS-CoV-2 infections in Qatar. The database was used to identify all SOT recipients who had a laboratory-confirmed SARS-CoV-2 infection by May 23, 2020. Demographic and clinical data were extracted from the hospital's electronic health records (Cerner Millennium, Cerner Corporation, Kansas City, Missouri, United States of America) during the period from May 25 to June 21, 2020. Final disposition was based on the patients' status on December 20, 2020. The outcomes assessed included COVID-19 severity according to the World Health Organization. Acute kidney injury (AKI) was defined according to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines.

COVID-19 diagnosis was confirmed using real-time polymerase chain reaction (RT-PCR) on airway specimens (Thermo Fisher Scientific, Waltham, Massachusetts). All patients received standard clinical care as per the local COVID-19 management guidelines. In addition to supportive care, individual patients received hydroxychloroquine, azithromycin, oseltamivir, lopinavir/ritonavir, darunavir/cobicistat, and/or tocilizumab. Specific regimens were selected by the treating physicians based on the disease severity and the presence of any organ dysfunction or potential drug-drug interactions. Decisions relating to immunosuppressive therapy were made by the attending transplant teams. Tacrolimus therapeutic drug levels were determined by an electro-chemiluminescence immunoassay (Roche Diagnostics, Rotkreuz, Switzerland) with a target reference range of 8.5 – 17 ng/mL.

Categorical data are presented as frequencies and percentages, while continuous variables are summarized as medians and ranges. Statistical analyses were performed using Microsoft Excel 2016 (Microsoft Corporation, Redmond, Washington, United States of America). The study protocol is consistent with the ethical guidelines of the 1975 Helsinki Declaration and was approved by the Institutional Review Board with a waiver of informed consent (MRC-01-20-191).

RESULTS

A total of 24 patients with SOT–associated COVID-19 were included. The majority were males (15, 62.5%), and the median age was 57 years (range 24 – 72). Organs received included the kidney (16, 66.7%),
liver (6, 25%), heart (1, 4.2%) and combined liver and kidney (1, 4.2%). The median time from transplant to COVID-19 diagnosis was 60 months (2 – 184).

Prior to COVID-19 diagnosis, all patients were independent for activities of daily living. Co-existing diabetes mellitus was present in 17 patients (70.8%), and cardiovascular disease in 4 (16.7%). Maintenance immune suppression therapy consisted of tacrolimus (FK) (21, 87.5%), mycophenolate mofetil (MMF) (21, 87.5%), prednisolone (PRD) (19, 79.2%), and/or cyclosporine (CsA) (3, 12.5%).

Five (20.8%) patients were asymptomatic at the time of COVID-19 diagnosis. Two patients were diagnosed during routine COVID-19 screening on return from travel, and two were screened when several members of their families were diagnosed with COVID-19. The fifth patient was a kidney recipient who was admitted with portal vein thrombosis without fever or respiratory symptoms (Table S1 in the supplementary file). For the remaining 19 patients, the median time between symptom onset and hospitalization was four days (1 – 14). The most frequent presenting symptoms were fever (15, 62.5%), cough (13, 54%), malaise (6, 25%), and dyspnea (6, 25%) (Table 1).

At presentation, median oxygen saturation was 96% (89 – 100). Median baseline laboratory findings included total peripheral white cell count of $5.4 \times 10^9$/L (1.9 – 8.7), lymphocyte count of $0.8 \times 10^9$/L (0.3 – 2.6), ferritin 539 µg/L (68 – 1161), and CRP 50.2 mg/L (0.3 – 203) (Table 1).

Baseline radiological abnormalities consistent with pneumonia were documented in 16 (66.7%) patients. Baseline characteristics of individual patients are summarized in Table S1 in the supplementary file. All patients received azithromycin. Other investigational therapies used are shown in Table 2. All but six patients had their maintenance immune suppressive therapy modified as part of their COVID-19 management. The most frequent changes were dose reduction or suspension of MMF (17/21, 81%) and tacrolimus (8/21, 38.1%). While systemic corticosteroids were not discontinued in any of the patients who were on maintenance prednisolone, the dose was increased in 12/19 (63.2%) patients, including all five who required invasive mechanical ventilation (Table 2, and Table S2 in the supplementary file).

The most frequently observed complication was AKI in association with high tacrolimus levels (23.3 ng/mL, 30.5 ng/mL, and 18.8 ng/mL) following the initiation of protease inhibitor augmentation as an investigational COVID-19 therapy (Table S2 in the supplementary file). By the end of follow-up, renal function returned to baseline in all three of these patients. One incident of AKI occurred in a patient with congestive heart failure and a concomitant urinary tract infection, and another in a patient who received concomitant trimethoprim-sulfamethoxazole. Both patients had had pre-existing chronic kidney graft dysfunction with estimated glomerular filtration rates below 30 mL/min and were still in hospital at the end of follow-up (Table S2 in the supplementary file). Other complications included acute liver dysfunction (9, 37.5%), none of which occurred in a liver transplant recipient.

Five (20.8%) patients required invasive mechanical ventilation for severe ARDS. Of these, two were successfully extubated and transferred to the medical floors after 24 and 33 days and were eventually discharged home, and one patient died after 26 days of admission. The remaining two patients had developed anoxic brain injury and were still in hospital at the end of follow-up (Table 2 and Table S2 in the supplementary file).

After a median follow-up period of 226 days (26 – 272), 20 patients (83.3%) had been discharged home or to a community isolation facility, 2 (8.3%) were still hospitalized in non-ICU areas, 1 (4.2 %) was still in ICU, and 1 (4.2%) had died (Table 2).

By end of follow-up, negative SARS-CoV-2 RT-PCR tests on airway samples were documented in 19 (79.2%) patients. Viral clearance in those patients occurred within 5 – 55 days from the first positive results (Table S2 in the supplementary file).

DISCUSSION

We herein report the clinical presentation, management, and outcomes of SOT-associated COVID-19 in Qatar. To control the epidemic, local authorities implemented several measures, including travel restrictions, social distancing interventions, and proactive screening of repatriated travelers and contacts of confirmed COVID-19 cases. A notable finding in this report is the proportion of SOT recipients with asymptomatic SARS-CoV-2 infections, which were only detected because of intensive case identification efforts. Asymptomatic COVID-19
Table S1. Baseline characteristics of 24 solid organ transplant recipients with SARS-CoV2 infection

| Case | Age (years) | Sex | Type of SOT | Month and year of transplant | Recent travel | Type of presentation | Date of 1st positive COVID-19 PCR | Lymphocyte count ($\times 10^9$/L) | Ferritin (µg/L) | CRP (mg/L) | Radiological findings |
|------|-------------|-----|-------------|------------------------------|--------------|---------------------|---------------------------------|---------------------------------|----------------|-------------|----------------------|
| 1    | 63          | Male| Kidney, deceased donor | June 2014 | None | Symptomatic | March 23, 2020 | 0.5 | 335 | 202.8 | Bilateral patchy infiltrates |
| 2    | 72          | Female| Heart, deceased donor | July 2007 | None | Symptomatic | April 3, 2020 | 0.7 | 1161 | 67.2 | Pulmonary congestion and pleural effusion |
| 3    | 62          | Female| Liver, living donor | April 2017 | Sri Lanka | Screening | March 30, 2020 | 1.3 | 328 | 0.3 | Unremarkable |
| 4    | 44          | Female| Liver, deceased donor | February 2020 | United Kingdom | Screening | April 3, 2020 | 0.6 | NA | 1.3 | Unilateral infiltrates |
| 5    | 61          | Female| Kidney, living donor | May 2015 | None | Symptomatic | April 14, 2020 | 0.7 | 658 | 116.4 | Bilateral patchy infiltrates |
| 6    | 40          | Male| Kidney, living donor | July 2018 | Philippines | Symptomatic | April 20, 2020 | 1.6 | 810 | 15.3 | Unremarkable |
| 7    | 46          | Male| Kidney, living donor | July 2015 | None | Symptomatic | April 25, 2020 | 2.6 | 362 | 5.0 | Bilateral patchy infiltrates |
| 8    | 40          | Male| Kidney, living donor | September 2019 | None | Symptomatic | April 30, 2020 | 0.68 | 72.9 | 48.4 | Bilateral patchy infiltrates |
| 9    | 62          | Female| Liver, deceased donor | November 2015 | None | Symptomatic | May 5, 2020 | 0.8 | 530 | 121 | Bilateral patchy infiltrates |
| 10   | 69          | Male| Kidney, living donor | June 2005 | None | Screening | May 8, 2020 | 1.3 | NA | 52 | Unremarkable |
| 11   | 54          | Male| Kidney, deceased donor | October 2015 | None | Symptomatic | May 3, 2020 | 0.77 | 930 | 39 | Unremarkable |
| 12   | 58          | Male| Kidney, living donor | January 2014 | None | Symptomatic | May 4, 2020 | 0.3 | 231 | 28.8 | Bilateral patchy infiltrates |
| 13   | 61          | Female| Kidney, living donor | December 2010 | None | Symptomatic | May 15, 2020 | 0.8 | 1055 | 46.1 | Bilateral patchy infiltrates |
| 14   | 47          | Male| Kidney, deceased donor | January 2016 | None | Symptomatic | May 15, 2020 | 0.8 | 173 | 31 | Unremarkable |
Table S1 – continued

| No. | Age | Sex | Diagnosis | Date | Source | Onset | Symptoms | CRP | ESR | Outcomes |
|-----|-----|-----|-----------|------|--------|-------|----------|-----|-----|----------|
| 15  | 52  | Male| Kidney, living donor | July 2016 | None | Symptomatic | May 15, 2020 | 1.5 | 822 | 97.6 | Bilateral patchy infiltrates |
| 16  | 55  | Male| Kidney, living donor | March 2013 | None | Screening | May 17, 2020 | 1.09 | 68.2 | 63 | Unremarkable |
| 17  | 72  | Male| Liver and kidney, deceased donors | November 2008 | None | Symptomatic | May 17, 2020 | 0.9 | 925 | 87.6 | Bilateral patchy infiltrates |
| 18  | 24  | Male| Liver, deceased donor | August 2016 | None | Screening | May 17, 2020 | 1.7 | 97.4 | 5.0 | Unremarkable |
| 19  | 58  | Male| Kidney, living donor | Feb 2008 | None | Symptomatic | May 18, 2020 | 0.6 | 868.0 | 113.8 | Bilateral patchy infiltrates |
| 20  | 59  | Male| Liver, deceased donor | June 2014 | None | Symptomatic | May 19, 2020 | 1.2 | 293.0 | 144.2 | Bilateral patchy infiltrates |
| 21  | 54  | Female| Kidney, living donor | Oct 2015 | None | Symptomatic | May 20, 2020 | 1.3 | 547 | 21.6 | Bilateral patchy infiltrates |
| 22  | 53  | Female| Kidney, living donor | April 2005 | None | Symptomatic | May 21, 2020 | 0.6 | 693.0 | 133.0 | Bilateral patchy infiltrates |
| 23  | 39  | Male| Liver, deceased donor | Jan 2016 | None | Symptomatic | May 21, 2020 | 0.7 | 775 | 5.2 | Bilateral patchy infiltrates |
| 24  | 60  | Female| Kidney, living donor | 2009* | None | Symptomatic | May 23, 2020 | 1.0 | 63.1 | Bilateral patchy infiltrates |

*Month of transplant is not available. COVID-19, Coronavirus Disease 2019; CRP, C-reactive protein.
cases are very well documented in general, and their role in sustaining the pandemic is becoming increasingly appreciated. However, to the best of our knowledge, this is the first time that asymptomatic SARS-CoV-2 infections are reported in SOT recipients.

### Table 1. Baseline characteristics of 24 solid organ transplant recipients with SARS-CoV-2 infection

| Characteristics                                      | All patients (n = 24) |
|------------------------------------------------------|-----------------------|
| Age, years                                           | 57 (24 – 72)          |
| Female sex                                           | 9 (37.5%)             |
| Transplant organ(s)                                  |                       |
| Kidney transplant                                    | 16 (66.7%)            |
| Liver transplant                                     | 6 (25%)               |
| Heart transplant                                     | 1 (4.2%)              |
| Kidney and liver transplant                          | 1 (4.2%)              |
| Time since transplant, months                        | 60 (1.7 – 184)        |
| Living donor                                         | 14 (58.3%)            |
| Travel-related COVID-19                              | 3 (12.5%)             |
| Diabetes mellitus                                    | 17 (70.8%)            |
| Cardiovascular disease                               | 4 (16.7%)             |
| Charlson Comorbidity Index Score                     | 3 (0 – 11)            |
| Maintenance immunosuppression                         |                       |
| Tacrolimus                                           | 21 (87.5%)            |
| Mycophenolate mofetil                                | 21 (87.5%)            |
| Prednisolone                                         | 19 (79.2%)            |
| Cyclosporine                                         | 3 (12.5%)             |
| Presenting symptoms                                  |                       |
| Asymptomatic                                         | 5 (20.8%)             |
| Fever                                                | 15 (62.5%)            |
| Cough                                                | 13 (54.2%)            |
| Sore throat                                          | 4 (16.7%)             |
| Malaise                                              | 6 (25%)               |
| Dyspnea                                              | 6 (25%)               |
| Nausea and vomiting                                  | 3 (12.5%)             |
| Days from symptom onset to hospitalization           | 4 (1 – 14)            |
| Baseline assessment                                  |                       |
| Oxygen saturation, %                                  | 96 (89 – 100)         |
| White blood cells, $\times 10^{9}$ cells/L           | 5.4 (1.9 – 8.7)       |
| Absolute neutrophil count, $\times 10^{9}$ cells/L   | 3.7 (1.2 – 7.2)       |
| Absolute lymphocyte count, $\times 10^{9}$ cells/L    | 0.8 (0.3 – 2.6)       |
| Ferritin, $\mu$g/L                                   | 539 (68 – 1161)       |
| C-reactive protein, mg/L                             | 50.2 (0.3 – 202.8)    |
| Radiological findings                                |                       |
| Unremarkable                                         | 7 (29.2%)             |
| Unilateral patchy infiltrates                         | 2 (8.3%)              |
| Bilateral patchy infiltrates                          | 14 (58.3%)            |
| Pulmonary congestion and pleural effusion            | 1 (4.2%)              |
| Initial disposition                                  |                       |
| Community isolation facility                          | 1 (4.2%)              |
| Hospitalized, non–ICU                                | 16 (66.7%)            |
| Hospitalized, ICU                                    | 7 (29.2%)             |

Figures represent n (%) or median (range). COVID-19, coronavirus disease 2019; ICU, intensive care unit; SARS–CoV–2, Severe Acute Respiratory Syndrome Coronavirus 2
Previous reports had suggested that SOT recipients are at increased risk of severe COVID-19. For example, one multi-center report from New York City included 90 SOT recipients with COVID-19, out of whom 24 (26.7%) required mechanical ventilation, and 16 (17.8%) died. Another single-center study from Madrid, Spain, described 18 SOT recipients with COVID-19; 4 (22.2%) developed progressive respiratory failure, and 5 (27.8%) died. On the other hand, in this report, only five patients (20.8%) required invasive mechanical ventilation, of which only one patient (4.2%) died. The low case fatality rate in this report and the satisfactory overall clinical outcomes cannot be fully explained by patient demographics. Several patients in this series recovered after developing organ failure. Those who required invasive mechanical ventilation were aged 53, 54, 58, 61, and 63 years; in contrast, the asymptomatic patients were aged 24, 44, 55, 62, and 69 years (Table S1 and Table S2 in the supplementary file).

Unlike a recent report of severe COVID-19 in a patient who presented shortly after liver transplantation, one patient in this study received a liver graft from a deceased donor only seven weeks prior to her diagnosis with asymptomatic SARS-CoV-2 infection (Patient 4 in Table S1 and Table S2). Rather...
Table S2. Management, complications, and outcomes of 24 solid organ transplant recipients with COVID-19

| Case | IST change | Investigational COVID-19 Therapies | Complications | Mechanical ventilation | ICU admission | Last available SARS-CoV2 PCR (result and days from first test) | Outcomes at end of follow-up |
|------|------------|----------------------------------|---------------|------------------------|--------------|---------------------------------------------------------------|-----------------------------|
| 1    | FK withheld, MMF withheld, PRD dose increased | HCQ, AZT, OST, DRV/c, RBV, TCZ | ARDS, AKI (stage 2), liver injury, gastric bleeding | IMV | Yes | negative (23 days) | Hospital discharge |
| 2    | FK continued, PRD continued | HCQ, AZT, OST | AKI (stage 1), anemia, congestive heart failure, UTI | NIV | Yes | negative (7 days) | Hospital discharge |
| 3    | FK continued, MMF dose reduced | HCQ, AZT, OST | None | None | No | negative (5 days) | Hospital discharge |
| 4    | FK continued, PRD continued | HCQ, AZT, OST | AKI (stage 1) | None | No | negative (22 days) | Hospital discharge |
| 5    | FK withheld, MMF withheld, PRD dose increased | HCQ, AZT, OST, LPV/r, TCZ | AKI (stage 2), rhabdomyolysis, ARDS, liver injury, anemia | IMV | Yes | negative (43 days) | Hospital discharge |
| 6    | FK continued, MMF withheld, PRD dose increased | HCQ, AZT, OST | Liver injury | None | No | negative (14 days) | Hospital discharge |
| 7    | FK dose reduced, MMF continued, PRD continued | HCQ, AZT, OST | Liver injury | None | No | positive (28 days) | Hospital discharge |
| 8    | FK withheld, MMF withheld, PRD dose increased | HCQ, AZT, OST | AKI (stage 1) | None | No | positive (25 days) | Hospital discharge |
| 9    | FK continued, MMF continued | HCQ, AZT, OST | None | None | No | negative (14 days) | Hospital discharge |
| 10   | FK continued, MMF dose reduced, PRD continued | HCQ, AZT | None | None | No | negative (14 days) | Hospital discharge |
| 11   | FK withheld, MMF withheld, PRD dose increased | HCQ, AZT, LPV/r, TCZ | ARDS, QTC prolongation, seizures, cardiorespiratory arrest, AKI (stage 3), liver injury, anoxic brain injury | IMV | Yes | negative (48 days) | Medical floor |
| 12   | FK continued, MMF withheld, PRD dose increased | HCQ, AZT, OST, LPV/r, TCZ | ARDS, hypertensive urgency, cardiorespiratory arrest, AKI (stage 2), liver injury, anoxic brain injury | IMV | Yes | negative (29 days) | Medical floor |
| 13   | FK dose decreased, MMF withheld, PRD dose increased | HCQ, AZT, OST, TCZ | Supraventricular tachycardia, AKI (stage 1), liver injury | NIV | Yes | negative (14 days) | Hospital discharge |
| Case | IST change | Investigational COVID-19 Therapies | Complications | Mechanical ventilation | ICU admission | Last available SARS-CoV2 PCR (result and days from first test) | Outcomes at end of follow-up |
|------|------------|-----------------------------------|---------------|------------------------|--------------|-------------------------------------------------|-----------------------------|
| 14   | FK continued | HCQ, AZT, OST | Liver injury | None | No | negative (14 days) | Hospital discharge |
| 15   | FK continued | HCQ, AZT, OST, TCZ | AKI (stage 1) | No | positive (8 days) | Hospital discharge |
| 16   | CsA continued | HCQ, AZT | Portal vein thrombosis, atrial fibrillation, ischemic cardiomyopathy, syncope | None | No | negative (8 days) | Hospital discharge |
| 17   | FK continued | HCQ, AZT | QTc prolongation | Tracheostomy | ICU | negative (38 days) | ICU |
| 18   | FK continued | AZT | None | None | No | negative (25 days) | Home (no hospital admission) |
| 19   | CsA continued | HCQ, AZT | Elevated myoglobin | None | No | negative (15 days) | Hospital discharge |
| 20   | FK continued | HCQ, AZT, OST | Hypoalbuminemia, AKI (stage 1) | None | No | negative (55 days) | Hospital discharge |
| 21   | FK continued | HCQ, AZT | None | No | positive (7 days) | Hospital discharge |
| 22   | FK reduce | HCQ, AZT, TCZ | ARDS, liver injury, pancreatitis, rhabdomyolysis, AKI (stage 3) | IMV | Yes | positive (22 days) | Died |
| 23   | FK dose decreased | HCQ, AZT | Leucopenia | None | No | negative (23 days) | Hospital discharge |
| 24   | CsA continued | HCQ, AZT, TCZ | None | None | No | negative (21 days) | Hospital discharge |

AKI, acute kidney injury; AZT, azithromycin; COVID-19, Coronavirus Disease 2019; CsA, cyclosporine; DRV/c, darunavir/cobicistat; FK, tacrolimus; HCQ, hydroxychloroquine; IMV, invasive mechanical ventilation; IST, immunosuppressive therapy; LPV/r, lopinavir/ritonavir; MMF, mycophenolate mofetil; NIV, noninvasive ventilation; OST, oseltamivir; PRD, prednisolone; RBV, ribavirin; TCZ, tocilizumab; UTI, urinary tract infection.
than a simple association between the type of graft and severity of COVID-19, the overall health status of the individual may be the most relevant factor. Large, preferably multi-center, cohort studies are urgently required to inform the risk assessment of SOT recipients with COVID-19 and to guide their medical management.

Despite widespread off-label use of hydroxychloroquine, azithromycin, and lopinavir/ritonavir for COVID-19, none of these agents has been proven clinically effective.\(^\text{11, 12}\) In addition to significant potential adverse events, such as cardiac arrhythmias and liver toxicity, these investigational agents could have detrimental interactions with immunosuppressants.\(^\text{11–13}\) As seen in this study and others, those interactions can result in toxicities that outweigh any potential benefits.\(^\text{14, 15}\) Moreover, it is not yet known if the immune-suppressed status of SOT recipients may ameliorate the inflammatory manifestations of COVID-19. Notably, dexamethasone use is associated with significantly reduced mortality in COVID-19 patients who require oxygen support.\(^\text{16}\) It is not yet clear if such a benefit is likely in SOT recipients who are already on a maintenance immune suppression regimen with or without corticosteroids.\(^\text{4}\)

Current recommendations for the management of severe COVID-19 in SOT recipients suggest that calcineurin inhibitors and MMF may be reduced or, if necessary, withheld, but the risk of graft dysfunction and rejection should be weighed very carefully against the risk of progressive COVID-19.\(^\text{17, 18}\) In this series, corticosteroids were either maintained or increased; MMF was continued the same, reduced or stopped; and tacrolimus doses were mostly changed only when potential interactions with investigational agents necessitated doing so. None of our patients experienced any evidence of acute rejection. It appears that a reasonable strategy in SOT recipients with COVID-19 is to maintain safe levels of immunosuppression while avoiding unproven investigational agents.\(^\text{18}\) Clinical studies are urgently required to examine the role of investigational COVID-19 therapies in SOT settings and to help determine the most appropriate immunosuppressive therapy modification to minimize the risk of both severe infection and graft rejection.\(^\text{17}\)

Patients in this study who cleared SARS-CoV-2 from their airways did so within as short a time span as 5 days and up to as long as 55 days or more. This is consistent with known variability in SARS-CoV-2 shedding, especially in patients with severe COVID-19.\(^\text{19}\)

### CONCLUSION

In conclusion, we report our experience thus far with COVID-19 in SOT recipients in Qatar. Proactive screening allowed the identification of asymptomatic SARS-CoV-2 infections. While some patients developed severe disease and required ICU support, the majority recovered without long-term complications. One patient died during follow-up. Our findings suggest that SOT-associated COVID-19 is not necessarily associated with a uniformly poor clinical outlook. Large clinical studies are required to better understand the clinical course of COVID-19 in SOT recipients, identify risk factors for severe disease, and determine the most appropriate management strategies.

### Disclosure

The authors declare no conflicts of interest.

### Funding

No funding was required.

### Data Availability

Data to support this report are available on reasonable request from the corresponding author.
A Review Article. Transplantation. 2021;105(1):37–55.

5. Siddiqi HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J Heart Lung Transplant. 2020;39(5):405–7.

6. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. Section 2: AKI Definition. Kidney Int Suppl (2011). 2012;2(1):19–36.

7. Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility – King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):377–81.

8. Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. COVID-19 in Solid Organ Transplant Recipients: Initial Report from The US Epicenter. Am J Transplant. 2020;20(7):1800–8.

9. Fernandez-Ruiz M, Andres A, Loinaz C, Delgado JF, Lopez-Medrano F, San Juan R, et al. COVID-19 in Solid Organ Transplant Recipients: A Single-Center Case Series from Spain. Am J Transplant. 2020;10.1111/ajt.15929.

10. Zhong Z, Zhang Q, Xia H, Wang A, Liang W, Zhou W, et al. Clinical Characteristics and Immunosuppressant Management of Coronavirus Disease 2019 in Solid Organ Transplant Recipients. Am J Transplant. 2020;20(7):1916–21.

11. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787–99.

12. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020;323(24):2493–502.

13. Monostory K. Metabolic Drug Interactions with Immunosuppressants. In: Tsoulfas G, editor. Organ Donation and Transplantation. Current Status and Future Challenges. IntechOpen. 2018. Available from: https://www.intechopen.com/books/organ-donation-and-transplantation-current-status-and-future-challenges/metabolic-drug-interactions-with-immunosuppressants.

14. Bartiromo M, Borchi B,otta A, Bagala A, Lugli G, Tili M, et al. Threatening Drug–Drug Interaction in a Kidney Transplant Patient with Coronavirus Disease 2019 (COVID-19). Transpl Infect Dis. 2020;22(4):e13286.

15. Meziyerh S, Zwart TC, van Etten RW, Janson JA, van Gelder T, Alwayn IPJ, et al. Severe COVID-19 in a Renal Transplant Recipient: A Focus on Pharmacokinetics. Am J Transplant. 2020;20(7):1896–901.

16. The RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693–704.

17. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy. Kidney Int Rep. 2020;5(5):580–5.

18. Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020;72(1):287–304.

19. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral Dynamics in Mild and Severe Cases of COVID-19. Lancet Infect Dis. 2020;20(6):656–7.